GPR68 Inhibition Drives Ferroptosis and Radiosensitization in Cancer Cells

Study Background and Research Question

Radioresistance—a major barrier to effective cancer therapy—often arises from the acidic tumor microenvironment, a consequence of the Warburg effect and lactic acid accumulation. While it is known that such acidification confers resistance to irradiation, the molecular mechanisms underlying this phenomenon remain incompletely understood. GPR68, a G-protein-coupled receptor sensitive to extracellular pH, is upregulated in multiple cancer types and implicated in pro-survival signaling under acidic conditions (Neitzel et al., 2025). The current study addresses whether inhibition of GPR68 can induce ferroptosis—a non-apoptotic, iron-dependent form of cell death—and sensitize cancer cells to radiotherapy.

Key Innovation from the Reference Study

The central innovation of Neitzel et al. lies in uncovering a mechanistic connection between GPR68 activity and ferroptosis susceptibility, expanding the known functions of this receptor beyond cell survival regulation. The study demonstrates that pharmacological or genetic inhibition of GPR68 not only induces ferroptosis in lung (A549) and pancreatic (Panc02) cancer cells but also synergizes with ionizing radiation to amplify lipid peroxidation and reduce clonogenic survival. This work identifies GPR68 as a critical mediator of the resistance phenotype in acidic tumoral niches and proposes its inhibition as a strategy for radiosensitization (Neitzel et al., 2025).

Methods and Experimental Design Insights

The research employed a combination of genetic and pharmacological approaches to interrogate GPR68's role in cancer cell survival and response to ferroptosis induction:

• CRISPR interference (CRISPRi): Used to knock down GPR68 expression in A549 and Panc02 cells. The specificity of gene targeting was validated by the absence of effect from dCas9 or sgRNA alone.
• siRNA and shRNA knockdown: Two distinct small interfering and short hairpin RNAs targeting GPR68 were used, each significantly reducing GPR68 transcript levels and cell viability compared to controls.
• Pharmacological inhibition: Ogremorphin (OGM), a selective GPR68 small molecule inhibitor, was applied to cancer cell lines to assess its effects on ferroptosis and radiosensitivity.
• Ferroptosis and viability assays: Lipid peroxidation—a hallmark of ferroptosis—was measured, along with clonogenic assays in both 2D and 3D cultures to evaluate cell survival post-treatment.
• Iron and ROS measurements: Intracellular free ferrous iron and reactive oxygen species were quantified to elucidate the mechanism by which GPR68 inhibition triggers ferroptosis (Neitzel et al., 2025).

Protocol Parameters

• cell viability assay | 72 hours | A549, Panc02 | To assess the impact of GPR68 knockdown on survival | paper
• lipid peroxidation assay | endpoint (post-OGM/radiation) | A549, Panc02 | Detects ferroptotic cell death via lipid ROS accumulation | paper
• clonogenic survival assay | 2D/3D cultures, varied radiation doses | A549, Panc02 | Measures long-term survival and radiosensitivity | paper
• ferrous iron quantification | post-GPR68 inhibition | A549, Panc02 | Links GPR68 blockade to iron-mediated ROS generation | paper
• oxidative stress assay | 24 hours, 10 μM Erastin | HT-1080, engineered tumor cells | Benchmarks ferroptosis induction for comparative studies | workflow_recommendation

Core Findings and Why They Matter

Neitzel et al. report several interlinked findings:

• Genetic or pharmacological inhibition of GPR68 significantly decreases cancer cell viability in both lung and pancreatic carcinoma models.
• GPR68 blockade alone induces ferroptosis, evidenced by increased lipid peroxidation and accumulation of intracellular ferrous iron. This implicates GPR68 in maintaining redox homeostasis and cell survival in the acidic tumor microenvironment.
• Combining GPR68 inhibition with ionizing radiation results in synergistic enhancement of ferroptotic cell death and reduced clonogenic survival in both 2D and 3D culture systems.
• The observed effects are specific to GPR68 targeting, as non-targeting controls do not elicit similar outcomes (Neitzel et al., 2025).

These findings matter because they establish GPR68 as a vulnerability in cancer cells that is both targetable and functionally linked to ferroptosis. Furthermore, the synergy with radiation offers a path to overcome intrinsic radioresistance by exploiting iron-dependent cell death pathways, which are independent of classical apoptotic mechanisms.

Comparison with Existing Internal Articles

Several internal resources provide context for the interpretation and application of ferroptosis inducers:

• The guide "Erastin (B1524): Scenario-Driven Solutions for Reliable Ferroptosis Assays" offers practical Q&A for experimental design, emphasizing Erastin as a model ferroptosis inducer in oxidative stress and viability assays. The workflow scenarios outlined complement the present study’s focus on assay reproducibility and mechanistic clarity.
• The article "Erastin: Ferroptosis Inducer and Redox Modulator for Cancer Biology" details Erastin's validated use in targeting RAS/BRAF-mutant tumor cells, providing a mechanistic benchmark for studies like Neitzel et al., where alternative ferroptosis triggers (GPR68 inhibition) are explored in diverse genetic backgrounds.
• Further, "Erastin in Ferroptosis Research: Mechanisms, Innovation, Outlook" provides a comprehensive review of Erastin’s role in experimental assays, which can inform comparative studies evaluating the effects of GPR68 inhibition versus system Xc⁻ blockade.

These resources collectively bridge the knowledge gap between established ferroptosis inducers like Erastin and emerging targets such as GPR68, supporting robust protocol development and mechanistic validation in cancer biology research.

Limitations and Transferability

Although Neitzel et al. demonstrate GPR68 inhibition-induced ferroptosis in lung and pancreatic cancer models, several limitations are evident:

• The work is primarily limited to in vitro systems (A549 and Panc02 cell lines), which may not fully recapitulate tumor microenvironment complexity in vivo.
• While synergy with radiation is shown in culture, the therapeutic benefit and safety of GPR68 inhibition in animal models or clinical settings remain to be established.
• The mechanistic details linking GPR68 activity to iron handling and redox regulation in different cancer types require further elucidation (Neitzel et al., 2025).

Transferability to other cancer types or to patient-derived samples should be validated, as GPR68 expression and function may vary across malignancies and microenvironmental contexts.

Research Support Resources

For researchers seeking to design robust ferroptosis and radiosensitivity assays, validated reagents are critical. Erastin (SKU B1524) from APExBIO is a well-characterized small molecule ferroptosis inducer widely used in oxidative stress and cell viability studies, particularly in RAS/BRAF-mutant tumor contexts (product_spec). Its established mechanism—modulation of system Xc⁻ and VDAC—provides a benchmark for comparative experiments alongside novel targets such as GPR68. When adapting protocols from Neitzel et al., Erastin can be included as a positive control or reference compound to validate assay sensitivity and reproducibility. Additional workflow guidance is available in internal scenario-driven articles (workflow_recommendation).